Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2017, 42(5): 281
ISSN 0377-8282
Copyright 2017 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2017.042.05.2625238
Repurposing nilvadipine for treatment of dementia: An overview
McCarthy, H., Kennelly, S., Crawford, F., Mullan, M., Cregg, F., Lawlor, B.A.
Given the significant societal challenges posed by Alzheimer's disease (AD), there is an urgent need to speed up the drug discovery process for this devastating neurodegenerative disease. The development of repurposed medications that have marketing authorization and a proven safety profile is a highly desirable approach. There is growing evidence that certain antihypertensive compounds may be protective, not just acting against vascular dementia, but also having benefits in AD. One antihypertensive currently being assessed for repurposing for AD is nilvadipine, a dihydropyridine (DHP) calcium channel antagonist. Animal studies have shown that nilvadipine decreases amyloid burden in transgenic mouse models of AD and early clinical studies have indicated a favorable safety profile for nilvadipine in AD patients. Based on the positive preclinical and clinical studies, a phase III trial of nilvadipine is currently being conducted across 23 clinical sites in 9 European countries (www.nilvad.eu) to determine the safety and efficacy of this medication in mild to moderate AD.

Full Text: PDF 

© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy